Bill & Melinda Gates Foundation is an investment fund managing more than $342 million ran by Connie Collingsworth. There are currently 10 companies in Mrs. Collingsworth’s portfolio. The largest investments include Curevac N V and Lumiradx Limited, together worth $217 million.
As of 8th November 2021, Bill & Melinda Gates Foundation’s top holding is 3,134,780 shares of Curevac N V currently worth over $171 million and making up 50.1% of the portfolio value.
In addition, the fund holds 5,574,059 shares of Lumiradx Limited worth $46.1 million.
The third-largest holding is BioNTech SE worth $40.6 million and the next is Vir Biotechnology Inc worth $29.5 million, with 677,777 shares owned.
Currently, Bill & Melinda Gates Foundation's portfolio is worth at least $342 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Bill & Melinda Gates Foundation office and employees reside in Seattle, Washington. According to the last 13-F report filed with the SEC, Connie Collingsworth serves as the Chief Operating Officer and Chief Legal Officer at Bill & Melinda Gates Foundation.
In the most recent 13F filing, Bill & Melinda Gates Foundation revealed that it had opened a new position in
Lumiradx Limited and bought 5,574,059 shares worth $46.1 million.
On the other hand, Connie Collingsworth disclosed a decreased stake in BioNTech SE by 0.9%.
This leaves the value of the investment at $40.6 million and 148,674 shares.
The two most similar investment funds to Bill & Melinda Gates Foundation are Ack Asset Management and Kirr Marbach & Co in/. They manage $342 million and $341 million respectively.
Bill & Melinda Gates Foundation’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 23.1% of
the total portfolio value.
The fund focuses on investments in the United States as
30.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
10% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $16 billion.
These positions were updated on November 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Curevac N V |
No change
3,134,780
|
$171,200,000 | 50.12% |
| Lumiradx Limited |
Opened
5,574,059
|
$46,100,000 | 13.50% |
| BioNTech SE |
85.69%
148,674
|
$40,600,000 | 11.89% |
| Vir Biotechnology Inc |
75.60%
677,777
|
$29,500,000 | 8.64% |
| Immuncore Hldgs Plc |
No change
576,923
|
$21,400,000 | 6.26% |
| Butterfly Network Inc |
No change
1,011,003
|
$10,600,000 | 3.10% |
| Atreca Inc |
No change
1,396,644
|
$8,700,000 | 2.55% |
| Sera Prognostics Inc |
Opened
779,814
|
$8,700,000 | 2.55% |
| Amyris Inc |
No change
292,398
|
$4,000,000 | 1.17% |
| Zymergen Inc |
No change
59,970
|
$800,000 | 0.23% |
| No transactions found | |||
| Showing first 500 out of 10 holdings | |||